Brown, Lisle/Cummings’s Eli Lilly LLY Stock Holding History

Brown, Lisle/Cummings’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.08M	Buy	3,353 +33	+1%	+$33.5K	0.77%	36
2025 Q4	$3.57M	Hold	3,320	–	–	0.88%	30
2025 Q3	$2.53M	Sell	3,320 -65	-2%	-$48.4K	0.65%	42
2025 Q2	$2.64M	Sell	3,385 -39	-1%	-$30.3K	0.7%	39
2025 Q1	$2.83M	Buy	3,424 +146	+4%	+$121K	0.82%	35
2024 Q4	$2.53M	Buy	3,278 +1,234	+60%	+$1.02M	0.76%	36
2024 Q3	$1.81M	Hold	2,044	–	–	0.55%	47
2024 Q2	$1.85M	Sell	2,044 -25	-1%	-$20K	0.6%	44
2024 Q1	$1.61M	Hold	2,069	–	–	0.55%	46
2023 Q4	$1.21M	Sell	2,069 -50	-2%	-$29.2K	0.45%	55
2023 Q3	$1.14M	Buy	2,119 +50	+2%	+$25.8K	0.52%	48
2023 Q2	$970K	Buy	2,069 +86	+4%	+$36.1K	0.43%	56
2023 Q1	$681K	Sell	1,983 -50	-2%	-$16.9K	0.35%	71
2022 Q4	$744K	Buy	2,033 +200	+11%	+$70.9K	0.4%	59
2022 Q3	$593K	Hold	1,833	–	–	0.35%	75
2022 Q2	$594K	Sell	1,833 -100	-5%	-$30K	0.33%	77
2022 Q1	$554K	Hold	1,933	–	–	0.27%	87
2021 Q4	$534K	Buy	+1,933	New	+$490K	0.27%	91

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Brown, Lisle/Cummings's LLY Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its Eli Lilly (LLY) stake by 0.99% in Q1 2026, buying an estimated $33.5K and bringing the position to 3,353 shares worth $3.08M. The position accounts for 0.77% of the portfolio, ranked #36.

Brown, Lisle/Cummings first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.57M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Brown, Lisle/Cummings held 3,353 shares of Eli Lilly worth $3.08M as of Q1 2026.
Brown, Lisle/Cummings bought 33 Eli Lilly shares in Q1 2026, an estimated $33.5K.
Eli Lilly made up 0.77% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #36 holding.
Brown, Lisle/Cummings first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
Brown, Lisle/Cummings's Eli Lilly position peaked at $3.57M in Q4 2025.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.